Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 7.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,476 shares of the company’s stock after purchasing an additional 227 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Krystal Biotech were worth $278,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of KRYS. Bank of New York Mellon Corp increased its stake in Krystal Biotech by 4.1% in the first quarter. Bank of New York Mellon Corp now owns 86,895 shares of the company’s stock valued at $5,782,000 after purchasing an additional 3,444 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Krystal Biotech by 54.4% in the first quarter. MetLife Investment Management LLC now owns 10,266 shares of the company’s stock valued at $683,000 after buying an additional 3,618 shares during the period. Rhumbline Advisers boosted its holdings in shares of Krystal Biotech by 10.0% in the first quarter. Rhumbline Advisers now owns 23,839 shares of the company’s stock valued at $1,586,000 after buying an additional 2,172 shares during the period. BlackRock Inc. boosted its holdings in shares of Krystal Biotech by 4.9% in the first quarter. BlackRock Inc. now owns 1,683,511 shares of the company’s stock valued at $112,020,000 after buying an additional 78,015 shares during the period. Finally, Great West Life Assurance Co. Can boosted its holdings in shares of Krystal Biotech by 51.9% in the first quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock valued at $72,000 after buying an additional 346 shares during the period. Institutional investors own 82.96% of the company’s stock.
Wall Street Analyst Weigh In
KRYS has been the subject of several research analyst reports. Stifel Nicolaus upped their price target on shares of Krystal Biotech from $102.00 to $145.00 in a report on Wednesday, May 24th. Chardan Capital upped their price target on shares of Krystal Biotech from $148.00 to $153.00 and gave the company a “buy” rating in a report on Monday, August 7th. Guggenheim upped their price target on shares of Krystal Biotech from $101.00 to $130.00 in a report on Monday, May 22nd. Bank of America upped their price target on shares of Krystal Biotech from $105.00 to $118.00 in a report on Sunday, May 21st. Finally, HC Wainwright restated a “buy” rating and set a $139.00 target price on shares of Krystal Biotech in a report on Monday, August 7th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $134.83.
Insiders Place Their Bets
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $116.16, for a total transaction of $2,904,000.00. Following the sale, the insider now directly owns 1,624,206 shares of the company’s stock, valued at $188,667,768.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $116.16, for a total transaction of $2,904,000.00. Following the sale, the insider now directly owns 1,624,206 shares of the company’s stock, valued at $188,667,768.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Janney sold 50,000 shares of the stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $95.02, for a total transaction of $4,751,000.00. Following the completion of the transaction, the director now directly owns 157,362 shares in the company, valued at $14,952,537.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 171,993 shares of company stock valued at $18,670,444. 17.00% of the stock is currently owned by corporate insiders.
Krystal Biotech Trading Up 1.4 %
Shares of KRYS opened at $121.96 on Wednesday. Krystal Biotech, Inc. has a 12 month low of $61.11 and a 12 month high of $131.80. The firm has a fifty day simple moving average of $122.28 and a 200 day simple moving average of $99.05. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of -22.46 and a beta of 0.81.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its quarterly earnings results on Monday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.02. As a group, research analysts predict that Krystal Biotech, Inc. will post -4.6 earnings per share for the current fiscal year.
Krystal Biotech Profile
Krystal Biotech, Inc, a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis.
Read More
- Five stocks we like better than Krystal Biotech
- The Dividend Kings With Highest Yield
- On Holding Slips Into A More Comfortable Price PointÂ
- The Significance of Brokerage Rankings in Stock Selection
- 3 Growing Cannabis Stocks Ready To Bloom
- The How and Why of Investing in Gold Stocks
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
